Literature DB >> 2842809

Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes.

S Z Langer1, S Arbilla.   

Abstract

At present, the nomenclature of benzodiazepine (BZ) receptors is based on its historical association with the BZ structure. However, it is mainly through the new compounds chemically unrelated to BZs that the central and peripheral subtypes of BZ receptors have been characterized. We therefore propose the nomenclature of a greek letter omega, as omega 1, omega 2 and omega 3 to designate respectively the central BZ1, BZ2 and the peripheral BZ receptor. Among the several classes of non-BZ drugs with affinity for different receptors, the imidazopyridines provide a valuable tool for the characterization of omega receptor subtypes. Most BZs are non selective ligands for the central omega 1 and omega 2 receptors while the selectivity for omega 1 receptor subtypes is present in several non BZ chemical series: imidazopyridines (zolpidem), triazolopyridazines (CL 218872), betacarbolines (beta-CCE) and pyrazoloquinolines (CGS 8216). Selective ligands for the omega 2 subtype are not available so far. The so called peripheral BZ receptor is also present in the central nervous system, therefore the proposed nomenclature of omega 3 receptors resolves this paradox because it does not designate location and it is defined in terms of pharmacological specificity. Selective ligands for omega 3 receptors include the BZ Ro 5-4864, and the isoquinolinecarboxamide PK 11195, while the imidazopyridine alpidem is the ligand with the highest affinity for this receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842809     DOI: 10.1016/0091-3057(88)90202-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  24 in total

Review 1.  The peripheral benzodiazepine receptors: a review.

Authors:  A Beurdeley-Thomas; L Miccoli; S Oudard; B Dutrillaux; M F Poupon
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 2.  GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.

Authors:  Raman Sankar
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 3.  Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future.

Authors:  A J Loonen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 4.  Prescribing short-acting hypnosedatives. Current recommendations from a safety perspective.

Authors:  D Wheatley
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

5.  Clinical pharmacokinetics and tolerability of alpidem in healthy subjects given increasing single doses.

Authors:  J H Jonkman; G Bianchetti; G Grasmeijer; B Oosterhuis; J F Thiercelin; J P Thénot; P Guillet; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Effect of psychotomimetics and some putative anxiolytics on stress-induced hyperthermia.

Authors:  A Lecci; F Borsini; L Gragnani; G Volterra; A Meli
Journal:  J Neural Transm Gen Sect       Date:  1991

7.  A comparison of the effects of zolpidem and placebo on respiration and oxygen saturation during sleep in the healthy elderly.

Authors:  S P Rhodes; P Parry; C D Hanning
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

Review 8.  Modulation and polytypic signaling in GABAergic transmission.

Authors:  J L Schlichting
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

Review 9.  The GABA-benzodiazepine interaction fifteen years later.

Authors:  W Haefely
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

10.  Discriminative stimulus effects of omega (BZ) receptor ligands: correlation with in vivo inhibition of [3H]-flumazenil binding in different regions of the rat central nervous system.

Authors:  D J Sanger; J Benavides
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.